Hypothermia Cap Market – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032
Overview
Hypothermia Cap Market was valued at USD 526.07 Mn in 2024 and is projected to reach USD 777.24 Mn, growing at a CAGR of 5%, driven by cancer cases and cooling tech innovation.
Hypothermia Cap Market Overview
A Hypothermia Cap, also known as a cooling cap, is a medical device used to lower the temperature of the scalp. It helps reduce hair loss during chemotherapy and is also used to protect the brain in conditions like neonatal encephalopathy, stroke, or cardiac arrest by slowing down brain activity and reducing damage.
The global Hypothermia Cap Market is witnessing robust growth, driven largely by increasing cancer cases and the effectiveness of cooling caps in preventing chemotherapy-induced alopecia. North America dominates the market due to high cancer incidence, advanced healthcare infrastructure, and strong regulatory support, accounting for over 40% of global revenue. One key driver is the growing clinical acceptance of therapeutic hypothermia in treating stroke, cardiac arrest, and neonatal encephalopathy. Government data highlights this trend: over 1.9 million new cancer cases were reported in the U.S. in 2022, and the ageing population is expected to rise from 12% to 22% globally by 2050. Top players like Paxman, Dignitana, and BrainCool AB lead due to FDA-approved technologies and strategic hospital partnerships. An emerging trend is the integration of AI-powered temperature control, improving safety and treatment outcomes.
In India, hypothermia or “medical caps” are typically classified under HSN 90189099, which saw 578 import shipments in the 12 months to August 2024, primarily from China, Germany, and the U.S. While specific import duty rates vary by material and use, these caps aren’t subject to special surcharges beyond standard customs duties—DSCR traders must file an Import Export Code (IEC) under the DGFT Foreign Trade Policy. In the U.S., hypothermia caps are duty-free when imported under relevant HTS codes, falling under general therapeutic devices with no additional tariffs.
To know about the Research Methodology :- Request Free Sample Report
Global Hypothermia Cap Market Dynamics
A report by Dawn L. Hershman published on 14 Feb 2021 in the JAMA Health Forum states that Scalp Cooling devices are proven effective to reduce Alopecia that has resulted as an adverse effect of the chemotherapy. The scientific validation for the use of Scalp cooling devices has resulted in increased use of the Hypothermia Cap by the Healthcare Industry.
A report by Lynn Weatherby published in the Journal of the Advanced Practitioner in Oncology states that the use of Hypothermia Cap 30 minutes before the chemotherapy has resulted in a 59% higher rate of hair retention. This report has resulted in increased preference for the Hypothermia Cap by cancer patients and is strongly recommended by medical practitioners.
A report by Christian Storm and others published in Springer Nature states that pre-hospital use of the Hypothermia Cap provides a safe, effective, easily available, and inexpensive way to start therapeutic hypothermia after cardiac arrest. This has resulted in the increased purchase of the Hypothermia Cap as a preliminary treatment device by people who are at risk of having cardiac attacks.
On July 3, 2017, the US Food and Drug Administration Agency has cleared the expanded use of the Hypothermia Cap to treat hair loss during chemotherapy, manufactured by DigniCap Cooling System.
An increase in the number of people suffering from chemotherapy-induced Alopecia is the driving factor for the growth of the Global Hypothermia Cap Market.
Global Hypothermia Cap Market Segment Analysis
Based on Type, it is observed that more than 75% of Hypothermia Caps present in the market are manufactured by using Neoprene, Silicone, and Polyurethane. The Neoprene segment dominates the Hypothermia Caps market in 2024. The demand for Hypothermia Cap applied with Glycerin has observed an increase of 2.1% in the US.
Based on the Application, it is observed that more than 60% of Hypothermia Caps manufactured are consumed by people suffering from Alopecia. The use of the Hypothermia Cap as a preliminary device to tackle cardiovascular diseases like stroke and cardiac arrest has resulted in a 7% increase in its sales. The use of the Hypothermia Cap for preventing cerebral palsy in babies born with neonatal encephalopathy has resulted in a 5% increase in demand for it by Pediatric Medical practitioners.
Based on End User, it is observed that Medical Device Distributors working for-profit or non-profit organisations working in the organised healthcare sector have observed a 7% increase in demand for the Hypothermia Cap. Hospitals with Oncology and Skincare departments that come under the organised sector have observed a 12% increase in demand for Hypothermia Caps. It is observed that Hospitals account for more than 75% of the revenue earned by the Global Hypothermia Cap Market.
A report by the WHO states that more than 75% of people suffering from Cancer undergo Chemotherapy. Hair Loss that happens due to Chemotherapy has resulted in an 8.7% increase in demand for Hypothermia caps by people suffering from cancer. Alopecia is a hair-related disease that results in the loss of hair on the scalp and body. An increase in the number of people suffering from natural or genetically based Alopecia has resulted in a 3% increase in the demand for Hypothermia caps. The use of the Hypothermia Cap as a pre-medical therapeutic instrument for reducing the effects of Cardiac Arrest has resulted in a 9% increase in its sales in the region of the US and Europe.
An increase in demand for Hypothermia Caps for inhibiting stroke paralysis has resulted in a 4% increase in demand from people suffering from cardiovascular diseases. The preference for the Hypothermia Cap to prevent cerebral palsy in babies born with neonatal encephalopathy has resulted in a 2.9% increase in sales to the Pediatric hospitals present in the US and Europe. Different medical issues that require cooling of the scalp use the Hypothermia Cap as needed.
Global Hypothermia Cap Market Regional Insights
North America dominates the Hypothermia Cap Market in 2024. Also, North America and Europe consume more than 48% of the Hypothermia caps manufactured in the world and contribute to more than 55% of the total revenue earned by the Global Hypothermia Cap Market. An increase in the number of people suffering from cancer and stroke has resulted in a 6% increase in demand for Hypothermia Caps in North America. The preference for therapeutic devices for Alopecia has resulted in a 4.3% increase in sales of Hypothermia Cap in Europe.
The ever-rising population and increase in the number of people suffering from cancer in countries like China, Australia, and India have resulted in a 2.8% increase in demand for Hypothermia Caps in the Asia-Pacific region. Lack of medical facilities and absence of medical infrastructure have resulted in low growth in South America. The Middle East and Africa region is showing a growth rate of 3%, the reason for which is the low incidence of cancer in this region. The growth of the Hypothermia Cap Market in this region is concentrated more in Israel, Jordan, and Egypt.
Hypothermia Cap Market Competitive Landscape
The Hypothermia Cap Market is moderately consolidated, with a few major players holding a significant share due to their technological advancements and global presence. Paxman leads the scalp cooling segment with its FDA-approved Paxman Scalp Cooling System, used in over 50 countries and backed by clinical trials and hospital partnerships. Dignitana, known for the DigniCap system, offers AI-integrated cooling caps that adjust temperature in real-time for optimal comfort and effectiveness. BrainCool AB focuses on multi-application hypothermia solutions like the BrainCool System Pro, catering to both oncology and neuro-intensive care units.
ZOLL Medical (USA) has expanded into hypothermia therapy through acquisitions and offers integrated patient monitoring and cooling systems. Cincinnati Sub-Zero provides a broad portfolio of thermal regulation equipment with advanced precision control, widely used in hospitals and emergency settings. These companies are at the top due to strong R&D, regulatory approvals, global distribution networks, and a focus on personalised, tech-enabled patient care. Their innovations align with growing medical trends like targeted temperature management and non-invasive therapies.
Hypothermia Cap Market Key Trends
• Growing Prevalence of Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
The increasing incidence of HIE in newborns is driving demand for hypothermia caps, as therapeutic hypothermia is a standard treatment. Approximately 1.5 per 1,000 live births result in HIE, with cooling caps being widely used to reduce brain damage.
• Technological Advancements in Cooling Systems
Innovations such as automated temperature control and portable cooling units are enhancing efficiency. Companies like Embrace Innovations and ZOLL Medical are introducing smart caps with real-time monitoring.
• Rising Awareness and Clinical Guidelines
The American Heart Association (AHA) and WHO recommend therapeutic hypothermia for HIE and cardiac arrest, increasing adoption. Over 70% of Level III NICUs in the U.S. now use cooling caps, with global awareness campaigns further propelling market growth.
Hypothermia Cap Market Recent Development
| Company | Date | Development |
| ZOLL Medical Corporation | 6-Jun-23 | Signed exclusive U.S. & Europe distribution deal for BrainCool/IQool System & pads under Asahi Kasei |
| BrainCool AB | 20-Mar-23 | Received NEMKO-issued CB certificate for new RhinoChill System key step toward EU MDR & US FDA listing |
| 20-Jul-23 | Secured EU patent for its BrainCool System’s anti-shivering technology; patent already granted in US, JP, CN, KR |
Hypothermia Cap Market Scope: Inquire before buying
| Hypothermia Cap Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2024 | Forecast Period: | 2025-2032 |
| Historical Data: | 2019 to 2024 | Market Size in 2024: | USD 526.07 Mn. |
| Forecast Period 2025 to 2032 CAGR: | 5% | Market Size in 2032: | USD 777.24 Mn. |
| Segments Covered: | by Type | Neoprene Silicone Polyurethane Glycerin Others |
|
| by Application | Neonatal encephalopathy Cardiac Arrest Alopecia Stroke Others |
||
| by End User | Hospital Medical Device Distributor Healthcare Center Others |
||
Hypothermia Cap Market, by region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Russia, Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Philippines, Malaysia, Vietnam, Thailand, Rest of Asia Pacific)
Middle East and Africa (South Africa, Saudi Arabia, UAE, Rest of the Middle East &Africa)
South America (Brazil, Argentina, Rest of South America)
Hypothermia Cap Market Key Players
North America
1. ZOLL Medical Corporation (USA)
2. Medline Industries, Inc. (USA)
3. Smiths Medical – ICU Medical (USA)
4. 3M Company (USA)
5. Life Recovery Systems HD, LLC (USA)
6. Cincinnati Sub-Zero – CSZ (Canada)
Europe
7. Drägerwerk AG & Co. KGaA (Germany)
8. BrainCool AB (Sweden)
9. Philips Healthcare – Royal Philips (UK)
10. Biegler GmbH (Germany)
11. The 37 Company (France)
12. EME Srl (Italy)
Asia Pacific
13. Nihon Kohden Corporation (Japan)
14. Beijing Medisystech Co., Ltd. (China)
15. Phoenix Medical Systems Pvt Ltd. (India)
16. Daewon Meditec Co., Ltd. (South Korea)
17. SWS Hemodialysis Care Co., Ltd. (China)
18. Atom Medical Corporation (Japan)
Middle East and Africa
19. Elmedix Ltd. (Israel)
20. Gulf Medical Co. Ltd. (UAE)
21. Sinapi Biomedical (South Africa)
South America
22. Fanem Ltda (Brazil)
23. Tecme S.A. (Argentina)
24. Magnamed (Brazil)
Frequently Asked Questions:
1. Which region has the largest share in the Global Hypothermia Cap Market?
Ans: North America dominates the Global Hypothermia Cap Market in 2024.
2. What is the growth rate of the Global Hypothermia Cap Market?
Ans: The Global Hypothermia Cap Market is growing at a CAGR of 5% during the forecasting period 2025-2032.
3. What is the scope of the Global Hypothermia Cap market report?
Ans: The Global Hypothermia Cap Market report helps with the PESTEL, Porter's, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in the Global Hypothermia Cap market?
Ans: The important key players in the Global Hypothermia Cap Market include ZOLL Medical Corporation, Medline Industries, Inc., Drägerwerk AG & Co. KGaA, BrainCool AB, Philips Healthcare, GE Healthcare, Smiths Medical (ICU Medical), and 3M Company.
5. What is the study period of this market?
Ans: The Global Hypothermia Cap Market is studied from 2024 to 2032.